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SUMMARY 
Background: The prevalence of metabolic syndrome (MetS) in patients with bipolar disorder is 35 to 40%. It is, however, not 
established yet whether MetS influences participation in physical activity, walking capacity and global functioning.  
Subjects and methods: Sixty-five patients (36 ♀) received a full-fasting laboratory screening, performed a walk test including 
self-report of pre- and post-test pain, and completed the International Physical Activity Questionnaire and the Quick Inventory of 
Depressive Symptomatology Self Report (QIDS-SR16).  
Results: Patients with (n=24) and without (n=41) MetS did not significantly differ in age, gender, psychotropic medication 
doses, physical activity, smoking behaviour and global functioning. In contrast, patients with MetS had a significantly (a) longer 
illness duration, (b) higher BMI, and (c) lower walking capacity. Moreover, patients with MetS scored significantly higher on the 
QIDS. Patients with MetS reported more pain before and after the walking test and more dyspnea following 6 minutes of walking, 
indicating the physical health challenges facing people with bipolar disorder and MetS seeking to engage in physical activity. 
Conclusion: The current data give further credence to the importance of interventions promoting the walking capacity in people 
with bipolar disorder, in particular in these patients at a high risk for cardiovascular diseases.  
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INTRODUCTION 
Metabolic and cardiovascular diseases (CVD) have 
become a major concern in patients with bipolar dis-
order (Babić et al. 2010, Prieto et al. 2014, Vancampfort 
et al. 2015a). Patients with bipolar disorder are known 
to have nearly twice the normal risk of dying from CVD 
(Osby et al. 2001). Genetic vulnerability (Ellingrod et 
al. 2012), illness-related inflammatory processes (Rosen-
blat & McIntyre 2015), cardio-metabolic side-effects of 
pharmacotherapy (Correll et al. 2015), and lifestyle 
factors including a sedentary lifestyle (Janney et al. 
2014), higher prevalence of substance abuse (Wax-
monsky et al. 2005), and a poor diet (Bernstein et al. 
2015) all contribute to the increased cardio-metabolic 
risk.  
The metabolic syndrome (MetS) might assist clini-
cians in identifying and treating patients at an increased 
risk of CVD. The MetS is defined by a combination of 
central obesity, high blood pressure, low high-density 
lipoprotein cholesterol, elevated triglycerides and hyper-
glycemia (Alberti et al. 2006). Recent meta-analyses 
demonstrated that the prevalence of MetS in patients 
with bipolar disorder is approximately 35 to 40% (Van-
campfort et al. 2013a, 2015b). A meta-analysis of longi-
tudinal studies reporting associations between MetS and 
cardiovascular events or mortality in the general 
population demonstrated that MetS is a predictor of 
cardiovascular events and death (Mottillo et al. 2010).  
Given the potential deleterious nature of MetS in 
people with bipolar disorder, clinicians should seek to 
address this risk. Switching psychotropic medications to 
those with lower metabolic liability and lifestyle 
changes such as smoking cessation, eating a healthy diet 
and participating in physical activity should be consi-
dered when managing MetS (Dadić-Hero et al. 2010, 
Vancampfort et al. 2015b). It is however difficult for 
people with bipolar disorder to adopt and maintain a 
healthy lifestyle (Vancampfort et al. 2015c). Barriers 
that are consistently reported in the literature are a lower 
self-efficacy, a lower educational status and lack of 
social support (Vancampfort et al. 2013b). Motivating 
the bipolar disorder subgroup who has MetS towards a 
more active lifestyle might be even more challenging. It 
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is known that in high-risk groups, once established, the 
MetS results often in lower physical activity partici-
pation and a reduced walking capacity (Gardner et al. 
2006, 2009, Vancampfort et al. 2011). One of the puta-
tive mechanisms is that MetS diminishes the peripheral 
circulation in the lower limbs (Chen et al. 2001). Poor 
peripheral circulation makes it difficult to participate in 
physical activities. This, in turn, creates a vicious circle 
of peripheral pain, physical inactivity, worsening of 
cardio-metabolic parameters, and progressive decline in 
walking capacity, deconditioning and consequently an 
impaired global functioning. For example, due to the 
physical health consequences of cardio-metabolic di-
seases, patients may not go to grocery stores, come for 
appointments, join social activities, engage in vocational 
activities or follow physical activity prescriptions. How-
ever, whilst a plausible relationship might exist, to date, 
it is not established yet if patients with bipolar disorder 
and MetS have a lower walking capacity, lower 
participation in physical activity, physical pain, and a 
lower global functioning.  
Therefore, the aim of this study was to determine if 
patients with bipolar disorder and MetS have an 
impaired walking capacity, lower physical activity 
levels, more self-reported physical pain and a lower 
global functioning compared with patients with bipolar 
disorder without MetS. 
 
SUBJECTS AND METHODS 
Participants and procedure 
Over a 9-month period, in- and outpatients with a 
DSM 5 diagnosis of bipolar disorder (American Psy-
chiatric Association 2013) admitted to the University 
Psychiatric Center KU Leuven, campus Kortenberg in 
Belgium were invited to participate. Reasons for admis-
sion were primarily due to either depressive or manic 
symptoms. Only participants with a clinical global 
impression severity scale (CGI-S) (Guy 1976) score of 
five or less, as assessed by a trained psychiatrist during 
a semi-structured interview were included. The CGI-S 
asks the clinician one question: “Considering your total 
clinical experience with this particular population, how 
mentally ill is the patient at this time?” which is rated on 
the following seven-point scale: 1=normal, not at all ill; 
2=borderline mentally ill; 3=mildly ill; 4=moderately 
ill; 5=markedly ill; 6=severely ill; 7=among the most 
extremely ill patients (Guy 1976). Patients admitted to 
the emergency psychiatric ward were excluded. Parti-
cipants were excluded if they had a current co-morbid 
DSM 5 diagnosis of substance abuse (American 
Psychiatric Association 2013) or if they met the 
absolute somatic contra-indications for exercise testing 
according to the American College of Sports Medicine 
(2013) (including evidence of significant cardio-
vascular, neuromuscular and endocrine disorders). All 
participants were medically cleared by a general physi-
cal examination and baseline electrocardiogram before 
testing. Participants received a full-fasting laboratory 
screening, performed a walk test, and completed the 
International Physical Activity Questionnaire and the 
Quick Inventory of Depressive Symptomatology Self 
Report (QIDS-SR16). The presence of MetS was asses-
sed using the International Diabetes Federation-criteria 
(Alberti et al. 2006). Illness duration was obtained from 
the patients’ medical records. The study procedure was 
conform the Declaration of Helsinki and approved by 
the Scientific and Ethical Committee of UPC KU 
Leuven, campus Kortenberg, Belgium in accordance 
with the principles of the Declaration of Helsinki. All 
participants gave their informed written consent. There 
was no compensation for participation in the study. 
 
Walking capacity 
The 6 minute walk test (6MWT) was performed 
according to the American Thoracic Society (2002) 
guidelines in an indoor hallway with a minimum of 
external stimuli. Two cones 25m apart indicated the 
length of the walkway. Participants were instructed to 
walk back and forth around the cones during 6 minutes, 
without running or jogging. Resting was allowed if 
necessary, but walking was to be resumed as soon as the 
participants were able to do so. The protocol stated that 
the testing was to be interrupted if threatening symp-
toms appeared, including (a) chest pain, (b) intolerable 
dyspnea, (c) leg cramps, (d) staggering, (e) diaphoresis, 
and (f) pale or ashen appearance. The total distance 
walked in 6 minutes was recorded to the nearest deci-
metre. Standardised encouragements were provided at 
recommended intervals. One mental health physical 
therapist supervised and measured all 6MWTs. The 
6MWT has been shown to be a valid and safe exercise 
test in patients with bipolar disorder (Vancampfort et al. 
2015d). 
 
Self-reported pain 
Prior to the 6MWT, participants were asked for pain 
that might interfere with their walking capacity. Spe-
cifically, participants were asked whether they 
experienced any foot problems or pain. Directly after 
the first test musculoskeletal pain in the lower limbs and 
dyspnea were recorded.  
 
Physical Activity Participation 
The International Physical Activity Questionnaire 
(IPAQ) (Craig et al. 2003) was used to assess the level 
of physical activity. The IPAQ asks participants to 
recall activities for each of the last seven preceding days 
in morning, afternoon, and evening time periods. On the 
basis of what activities participants self-reported, the 
interviewer (a physical therapist) also clarified the 
perceived intensity of that specific activity. A 
continuous indicator was calculated as a sum of weekly 
metabolic equivalent (MET)-minutes per week of 
physical activity. The MET energy expenditure was 
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estimated by weighting the reported minutes per week 
by a MET energy expenditure estimate for each type of 
activity (low, moderate and vigorous intensity physical 
activity). The weighted MET-minutes per week were 
calculated as duration x frequency per week x MET-
intensity, which were then summed to produce a 
weighted estimate of the total physical activity from all 
reported activities per week as per the IPAQ scoring 
protocol. Previous research indicated that the IPAQ 
can be considered as a valid tool to assess differences 
in levels of physical activity in patients with bipolar 
disorder, although with caution as active energy 
expenditure might be overestimated (Vancampfort et 
al. 2015e). 
 
Quick Inventory of Depressive Symptomatology 
Self Report (QIDS-SR16) 
The QIDS-SR16 (Rush et al. 2003) consists of 16 
items that assess the nine symptom domains used to 
diagnose a major depressive episode. The responses for 
each item range from 0 to 3, with 0 indicating the 
absence of that symptom in the past week. The total 
score ranges from 0 to 27.  
 
Global Assessment of Functioning (GAF) score 
The GAF (American Psychiatric Association 2000) 
combines the evaluation of symptoms as well as 
relational, social, and occupational functioning on a 
single axis. The scale runs from one to 100 and is 
divided into 10 equal parts providing defining 
characteristics, both symptoms and functioning, for each 
10-point interval. A low rating reflects worse symptoms 
and a poorer level of functioning, whereas a high rating 
reflects less symptoms and a better level of functioning. 
The GAF was recorded by the treating psychiatrist as a 
single score reporting only the most severe of the 
symptom and functioning values. The GAF score is 
known to be a valid measure of global functioning in 
patients with severe mental illness (Jones et al. 1995). 
 
Anthropometric assessments 
Body weight was measured by the (blinded) research 
nurse in light clothing to the nearest 0.1 kg using a 
SECA beam balance scale, and height to the nearest 0.1 
cm using a wall-mounted stadiometer.  
 
Smoking behaviour 
Participants were asked whether they smoked or not, 
and if so, how many cigarettes they smoke per day on 
average.  
 
Medication use 
Current antipsychotic medication use was recorded 
for each patient and the daily dosage of each anti-
psychotic was converted into a daily equivalent dosage 
of chlorpromazine following the consensus of Gardner 
et al. (2010). If patients were treated with a combina-
tion of antipsychotics, all obtained equivalent dosages 
of chlorpromazine were summed together. Next to 
antipsychotic medication use, we also assessed the 
daily dosage of mood stabilizers if present in at least 
10 participants. 
 
Statistical analysis 
Unpaired t-tests were used to assess whether 
differences in the characteristics existed between bipolar 
disorder patients with and without MetS. For differences 
in gender distribution the Fisher Exact Test was used. A 
Bonferroni correction was applied to adjustment for 
multiple comparisons by dividing the significance 
level 0.05 by the number of comparisons, in this case 
0.05/20=0.0025. Pearson's correlations were calculated 
between clinical and demographical variables that 
differed in those with and without MetS group. 
Significance for the correlation analyses was set at 
p<0.05. Statistical analyses were performed using the 
statistical package SPSS version 22.0 (SPSS Inc., 
Chicago, IL). 
 
RESULTS 
Participants 
Out of 85 persons with bipolar disorder, 73 met the 
inclusion criteria of which 8 declined to participate. 
Reasons for exclusion are presented in Figure 1. The 
gender distribution of the final included sample was 29 
men (45.1±9.8years; BMI=26.7±3.0) and 36 women 
(43.8±11.6years; BMI=25.8±5.2). Across the entire 
sample, age ranged from 19 to 64 years. There were 19 
outpatients (47.8±7.9years; BMI=26.3±5.2) and 46 
inpatients (42.9±11.6years; BMI=26.1±4.0). All indi-
viduals were Caucasians. 
 
 
Figure 1. Flow chart of the eligible in- and outpatients 
with bipolar disorder 
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Table 1. Clinical characteristics of bipolar disorder patients with and without metabolic syndrome (MetS) 
Variables Non-MetS group (n=41) MetS group (n=24) p 
Age (years) 42.8±10.3 47.0±11.3 0.140 
Gender 
Male 
Female  
 
21 (72.4%) 
20 (55.6%) 
 
8 (27.6%) 
16 (44.4%) 
0.070 
Setting   0.100 
Inpatients  18 (50%) 18 (50%)  
Outpatients  13 (66.7%) 6 (33.3%)  
Illness duration (years) 12.5±9.0 22.2±10.7 <0.001* 
GAF score 59.0±12.7 48.1±16.4 0.004 
IPAQ (MET-min/week) 1704.8±1151.9 1014.2±709.4 0.010 
QIDS score 5.8±5.1 10.9±5.2 <0.001* 
6MWT score (m) 658.0±103.5 543.2±108.9 <0.001* 
Foot problems or pain pre (%) 
Yes  
Non  
 
4 (23.5%) 
37 (80.4%) 
 
13 (76.5%) 
11 (19.6%) 
<0.001* 
Musculoskeletal problems post 
Yes  
Non 
 
6 (33.3% 
35 (76.0%) 
 
13 (66.7%) 
11 (24.0%) 
<0.001* 
Dyspnea post  
Yes  
Non 
 
0 (0%) 
54 (100%) 
 
11 (100%) 
0 (0%) 
<0.001* 
Variables Non-MetS group MetS group p 
Number of cigarettes (n=22: 16 vs. 6) 16.4±12.2 20.9±12.9 0.51 
Chlorpromazine eq (mg/day) (n=52: 34 vs. 18) 381.8±267.5 446.9±296.6 0.42 
Lithium carbonate (mg/day) (n=23: 15 vs. 8) 825.0±523.2 833.3±422.8 0.97 
Valproic acid (mg/day) (n=14: 8 vs. 6) 1575.0±661.2 1666.7±491.6 0.78 
Values expressed as mean ± standard deviation or as otherwise indicated;   *Significant when P<0.0025 (Bonferonni-
corrected: 0.05/20=0.0025);   GAF = Global Assessment of Functioning;   IPAQ = International Physical Activity 
Questionnaire;   QIDS = Quick Inventory of Depressive Symptomatology;   6mWT = 6minute walk test;   eq = equivalents 
 
Differences between patients  
with and without MetS 
Twenty-four (36.9%) patients with bipolar disorder 
met the IDF-criteria (Alberti et al. 2006) for MetS. The 
demographical and clinical characteristics of the 
patients with and without MetS are presented in Table 1. 
After Bonferroni correction, there were no significant 
(p<0.0025) differences between both groups regarding 
age, gender, psychotropic medication doses, physical 
activity and smoking behaviour and global functioning. 
In contrast, patients with MetS had a significantly (a) 
longer illness duration, and (b) a lower walking 
capacity. Patients with bipolar disorder and MetS also 
scored significantly higher on the QIDS. Lastly, patients 
with MetS reported more physical pain before and after 
the walking test and more dyspnea following 6 minutes 
of walking.  
 
Factors associated with walking capacity  
in patients with MetS  
In patients with MetS, the 6MWT was significantly 
associated with illness duration (r=-0.43, p=0.036), and 
the QIDS (r=-0.48, p=0.017). 
DISCUSSION 
To the authors’ knowledge this is the first study 
demonstrating that bipolar disorder patients with MetS 
have an impaired walking capacity, and more self-
reported physical pain compared with patients without 
MetS. Previous research reported that patients with 
bipolar disorder walked 16.1% shorter on a 6MWT 
compared to age and gender matched healthy volun-
teers (Vancampfort et al. 2015f). The present data add 
that the presence of MetS places patients with bipolar 
disorder at an even greater risk for a reduced walking 
capacity. 
The current findings provide several hypotheses for 
the impaired walking capacity. First, patients with MetS 
had a higher BMI and reported more physical pain 
before and after the walk test. Obesity consistently 
emerges as a key and potentially modifiable risk factor 
in the onset and progression of musculoskeletal condi-
tions and pain (Wearing et al. 2006), which on its turn 
impairs the ability to perform weight-bearing activities 
such as walking. It is known as well that the MetS is 
associated with an increased incidence of lower 
extremity peripheral artery disease (Vidula et al. 2015), 
which is also associated with physical limitations 
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induced by ambulatory leg pain (McDermott et al. 
2001). Second, our data show that bipolar disorder 
patients with MetS have more depressive sympto-
matology compared with those not having MetS, and 
these depressive symptoms were associated with the 
walking capacity. It might be speculated that those who 
are depressed are less likely to engage in a healthy 
lifestyle which on its turn might result in a lower 
walking capacity. However, after the Bonferroni correc-
tion we did not find significant differences in physical 
activity participation between patients with and without 
MetS. Also a lower self-efficacy and more negative 
outcome expectations patients with depression are often 
confronted with when performing physical fitness tests 
may result in a worse test performance (Krämer et al. 
2014). Next to this psychological hypothesis, low-grade 
inflammation associated with the manifestation of 
depressive symptoms (Leboyer et al. 2012) should be 
tested more in detail. Inflammatory processes may cause 
pathological microvascular changes that can affect gas 
transfer across the alveolar-capillary membrane, which 
in turn may affect the circulatory, respiratory, and 
muscular systems involved in supplying oxygen to the 
body (Ostermann et al. 2013). The observation that all 
patients with dyspnea had MetS offers a strong rationale 
for this hypothesis. A previous pilot study in patients 
with schizophrenia already demonstrated that the 
presence of MetS is associated with an increased 
prevalence of restrictive lung dysfunction (Vancampfort 
et al. 2014). The longer illness duration observed in 
patients with MetS, and consequently a longer lifetime 
exposure to depressive symptoms in this group, may 
also point into the direction of a chronic low-grade 
inflammation hypothesis. 
The findings of the present study must be interpreted 
with caution because of some methodological limi-
tations. An important limitation was the reliance on self-
reported physical activity, a method that is prone to both 
systematic and random errors (Soundy et al. 2014). 
Secondly, the single-centre nature of our study limits 
the generalizability. Present findings need to be repli-
cated in a larger multicentre study. Thirdly, data on 
eating habits and substance abuse as risk factors for 
MetS and the level of manic symptoms were not 
assessed. Lastly, the current study had a cross-sectional 
nature. Thus, the impact of MetS risk and the effects of 
behaviour modification could not be estimated directly.  
This study adds to current knowledge that bipolar 
disorder patients with MetS have a reduced walking 
capacity. Patients with MetS may therefore be at greater 
risk for mobility decline than patients who do not have 
MetS. Multidisciplinary treatment protocols designed to 
reduce the risk factors of MetS should not only focus on 
decreasing CVD risks but should also target physical 
function improvements in daily life activities. Speci-
fically, we have established that patients with MetS 
report more musculoskeletal pain in lower limbs. Since 
patients with bipolar disorder experience a double 
increased risk for chronic pain (Stubbs et al. 2015a) and 
pain in the lower limbs seems to be associated with 
cardio-metabolic and musculoskeletal conditions, strate-
gies to encourage patients with bipolar disorder to 
become more physically active which do not exacerbate 
pain are likely to be key in improving the functional 
outcome of these patients. Physical therapists should 
lead in the assessment and management of musculo-
skeletal pain among people with bipolar disorder, who 
can offer appropriate adaptive and rehabilitation exer-
cises to improve pain symptoms. The importance of 
addressing pain in people with serious mental illness is 
rising giving our findings and those of another recent 
study demonstrating pain is independently associated 
with worse quality of life and more depressive symp-
toms (Stubbs et al. 2015b).  
Future intervention studies are highly needed to 
extend the preliminary findings of the current study. 
Future research should also focus on the possible 
negative consequences that MetS may have in patients 
with bipolar disorder on ambulation and especially on 
the peripheral circulation in the lower limbs. Impaired 
peripheral circulation could be assessed measuring calf 
blood flow during a 6MWT by using a mercury strain-
gauge plethysmography or by measuring transcutaneous 
oxygen tension (TcPO2) with a polarographic electrode 
and a TcPO2 Monitor. 
 
CONCLUSIONS 
The present study demonstrates that the functional 
exercise capacity is impaired in bipolar disorder patients 
with MetS. Future research should investigate more in 
detail underlying mechanisms such as musculoskeletal 
and cardio-metabolic complications (impaired peri-
pheral circulation) of the MetS and a long-term 
exposure to depressive symptoms. The current data give 
further credence to the importance of interventions 
promoting the walking capacity in people with bipolar 
disorder, in particular in these patients at a high risk for 
CVD.  
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